To add or not to add a new treatment arm to a multiarm study: A decision‐theoretic framework
暂无分享,去创建一个
[1] J. Wason,et al. Correcting for multiple-testing in multi-arm trials: is it necessary and is it done? , 2014, Trials.
[2] Giovanni Parmigiani,et al. Adaptive Randomization of Neratinib in Early Breast Cancer. , 2016, The New England journal of medicine.
[3] J. Q. Smith. Decision Analysis: A Bayesian Approach , 1988 .
[4] P. Bauer,et al. Evaluation of experiments with adaptive interim analyses. , 1994, Biometrics.
[5] Jack Bowden,et al. Identifying combined design and analysis procedures in two-stage trials with a binary end point , 2012, Statistics in medicine.
[6] Nigel Stallard,et al. A comparison of methods for constructing confidence intervals after phase II/III clinical trials , 2014, Biometrical journal. Biometrische Zeitschrift.
[7] L. Joseph,et al. Bayesian Statistics: An Introduction , 1989 .
[8] Stefanie Biedermann,et al. Optimal design for experiments with possibly incomplete observations , 2018 .
[9] Martin Posch,et al. Decision-theoretic designs for small trials and pilot studies: A review , 2015, Statistical methods in medical research.
[10] Howard Raiffa,et al. Applied Statistical Decision Theory. , 1961 .
[11] Nigel Stallard,et al. Point estimates and confidence regions for sequential trials involving selection , 2005 .
[12] Brian P Hobbs,et al. Controlled multi-arm platform design using predictive probability , 2018, Statistical methods in medical research.
[13] N. Lane,et al. Cryoneurolysis to treat the pain and symptoms of knee osteoarthritis: a multicenter, randomized, double-blind, sham-controlled trial. , 2017, Osteoarthritis and cartilage.
[14] J. Wason,et al. Optimal multistage designs for randomised clinical trials with continuous outcomes , 2011, Statistics in medicine.
[15] Lorenzo Trippa,et al. Adding experimental arms to platform clinical trials: randomization procedures and interim analyses. , 2018, Biostatistics.
[16] D A Berry,et al. One-sided sequential stopping boundaries for clinical trials: a decision-theoretic approach. , 1988, Biometrics.
[17] W. Brannath,et al. Recursive Combination Tests , 2002 .
[18] M. Degroot. Optimal Statistical Decisions , 1970 .
[19] Nigel Stallard,et al. Sequential designs for phase III clinical trials incorporating treatment selection , 2003, Statistics in medicine.
[20] Thomas Jaki,et al. Some recommendations for multi-arm multi-stage trials , 2012, Statistical methods in medical research.
[21] Martin Posch,et al. Optimal choice of the number of treatments to be included in a clinical trial , 2009, Statistics in medicine.
[22] Brian M Alexander,et al. Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE , 2017, Clinical Cancer Research.
[23] Martin Posch,et al. Determination of the optimal sample size for a clinical trial accounting for the population size , 2016, Biometrical journal. Biometrische Zeitschrift.
[24] Ying Yuan,et al. MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents. , 2016, Statistics in medicine.
[25] Nigel Stallard,et al. Optimal sample sizes for phase II clinical trials and pilot studies , 2012, Statistics in medicine.
[26] G. Parmigiani,et al. Designing Clinical Trials That Accept New Arms: An Example in Metastatic Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Wenle Zhao,et al. Flexible Analytical Methods for Adding a Treatment Arm Mid-Study to an Ongoing Clinical Trial , 2012, Journal of biopharmaceutical statistics.
[28] M. Parmar,et al. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial , 2012, Trials.
[29] Jack Bowden,et al. Response‐adaptive designs for binary responses: How to offer patient benefit while being robust to time trends? , 2017, Pharmaceutical statistics.
[30] S. Todd,et al. Adding a treatment arm to an ongoing clinical trial: a review of methodology and practice , 2015, Trials.
[31] Nigel Stallard,et al. Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility , 2013, Statistics in medicine.
[32] Alex Dmitrienko,et al. POWER CALCULATIONS IN CLINICAL TRIALS WITH COMPLEX CLINICAL OBJECTIVES , 2015 .
[33] Kim May Lee,et al. Optimal design when outcome values are not missing at random , 2018 .
[34] J. Wason,et al. Minimizing the Maximum Expected Sample Size in Two-Stage Phase II Clinical Trials with Continuous Outcomes , 2012, Journal of biopharmaceutical statistics.
[35] Nigel Stallard,et al. Uniformly minimum variance conditionally unbiased estimation in multi-arm multi-stage clinical trials , 2018 .
[36] Jack Bowden,et al. A multi-stage drop-the-losers design for multi-arm clinical trials , 2016, Statistical methods in medical research.
[37] Tim Friede,et al. A group‐sequential design for clinical trials with treatment selection , 2008, Statistics in medicine.
[38] Adrian P Mander,et al. Admissible two‐stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis , 2012, Pharmaceutical statistics.
[39] Thomas Jaki,et al. Optimal design of multi‐arm multi‐stage trials , 2012, Statistics in medicine.